Elevated preoperative serum asymmetrical dimethylarginine (ADMA) is associated with poor outcomes after pediatric cardiac surgery

[1]  D. Chace,et al.  Evaluation of asymmetric dimethylarginine, arginine, and carnitine metabolism in pediatric sepsis , 2012, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[2]  S. Goldstein,et al.  Fluid overload is associated with impaired oxygenation and morbidity in critically ill children* , 2012, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[3]  C. Krawczeski,et al.  Incidence, risk factors, and outcomes of acute kidney injury after pediatric cardiac surgery: A prospective multicenter study* , 2011, Critical care medicine.

[4]  E. Schwedhelm,et al.  The role of asymmetric and symmetric dimethylarginines in renal disease , 2011, Nature Reviews Nephrology.

[5]  J. Boffa,et al.  Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF‐β1 synthesis , 2011, The Journal of pathology.

[6]  P. D. del Nido,et al.  The Relationship Between Inflammatory Activation and Clinical Outcome After Infant Cardiopulmonary Bypass , 2010, Anesthesia and analgesia.

[7]  C. Krawczeski,et al.  Serum cystatin C is an early predictive biomarker of acute kidney injury after pediatric cardiopulmonary bypass. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[8]  F. Horkay,et al.  Strong relationship between NT‐proXNP levels and cardiac output following cardiac surgery in neonates and infants , 2010, Acta anaesthesiologica Scandinavica.

[9]  C. Altmann,et al.  Serum Interleukin-6 and interleukin-8 are early biomarkers of acute kidney injury and predict prolonged mechanical ventilation in children undergoing cardiac surgery: a case-control study , 2009, Critical care.

[10]  Susan L Furth,et al.  New equations to estimate GFR in children with CKD. , 2009, Journal of the American Society of Nephrology : JASN.

[11]  E. Brooks,et al.  Methylated arginine derivatives in children and adolescents with chronic kidney disease , 2009, Pediatric Nephrology.

[12]  Carmine Zoccali,et al.  Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease , 2008, Current opinion in nephrology and hypertension.

[13]  Q. Shu,et al.  Perioperative risk factors for prolonged mechanical ventilation following cardiac surgery in neonates and young infants. , 2008, Chest.

[14]  P. Gambert,et al.  Impact of Asymmetric Dimethylarginine on Mortality After Acute Myocardial Infarction , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[15]  M. Mitsnefes,et al.  Plasma neutrophil gelatinase-associated lipocalin predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study , 2007, Critical care.

[16]  T. Karl,et al.  B-type natriuretic peptide levels predict outcomes for children on extracorporeal life support after cardiac surgery. , 2007, The Journal of thoracic and cardiovascular surgery.

[17]  D. Tsikas,et al.  Elevated asymmetric dimethylarginine (ADMA) and inverse correlation between circulating ADMA and glomerular filtration rate in children with sporadic focal segmental glomerulosclerosis (FSGS). , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  P. Tsao,et al.  Asymmetrical Dimethylarginine in Renal Disease: Limits of Variation or Variation Limits? , 2007, American Journal of Nephrology.

[19]  A. Åsberg,et al.  Health‐associated reference values for arginine, asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) measured with high‐performance liquid chromatography , 2007, Scandinavian journal of clinical and laboratory investigation.

[20]  Carmine Zoccali,et al.  Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. , 2005, Journal of the American Society of Nephrology : JASN.

[21]  F. Kronenberg,et al.  Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. , 2005, Journal of the American Society of Nephrology : JASN.

[22]  Qing Ma,et al.  Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery , 2005, The Lancet.

[23]  H. Blau,et al.  Overexpression of Dimethylarginine Dimethylaminohydrolase Reduces Tissue Asymmetric Dimethylarginine Levels and Enhances Angiogenesis , 2005, Circulation.

[24]  J. Himmelfarb.  POOR NUTRITIONAL STATUS AND INFLAMMATION: Linking Oxidative Stress and Inflammation in Kidney Disease: Which is the Chicken and Which is the Egg? , 2004 .

[25]  M. Yamaguchi,et al.  Evaluation of heart fatty acid-binding protein as a rapid indicator for assessment of myocardial damage in pediatric cardiac surgery. , 2004, The Journal of thoracic and cardiovascular surgery.

[26]  R. Nijveldt,et al.  Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. , 2003 .

[27]  K. Gauvreau,et al.  Center-specific differences in mortality: preliminary analyses using the Risk Adjustment in Congenital Heart Surgery (RACHS-1) method. , 2002, The Journal of thoracic and cardiovascular surgery.

[28]  C. Zoccali,et al.  Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study , 2001, The Lancet.

[29]  M. Gorenflo,et al.  Plasma Levels of Asymmetrical Dimethyl-l-Arginine in Patients with Congenital Heart Disease and Pulmonary Hypertension , 2001, Journal of cardiovascular pharmacology.

[30]  S. Bode-Böger,et al.  Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. , 1999, Journal of the American Society of Nephrology : JASN.

[31]  C. Baylis,et al.  Chronic nitric oxide inhibition model six years on. , 1998, Hypertension.

[32]  L. Lindberg,et al.  Serum S-100 protein levels after pediatric cardiac operations: a possible new marker for postperfusion cerebral injury. , 1998, The Journal of thoracic and cardiovascular surgery.

[33]  J. Mayer,et al.  Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest. , 1995, Circulation.

[34]  S. Moncada,et al.  Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure , 1992, The Lancet.

[35]  E. Brooks,et al.  Measurement of arginine derivatives in pediatric patients with chronic kidney disease using high-performance liquid chromatography-tandem mass spectrometry , 2007, Clinical chemistry and laboratory medicine.

[36]  D. Fliser,et al.  Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. , 2002, Journal of the American Society of Nephrology : JASN.